at the speed covid-19 is spreading through the world, a vaccine may be the only way to stop it in its tracks. but as people continue to die, and experts say that a vaccine may be a whopping 18 months away, it’s worth looking into the past and see what kinds of stopgap measures could be a possibility as we wait.
this form of passive immunity was first tried on diphtheria patients in the late 1800s, and has since been used to manage many diseases , including ebola, sars, and mers.
researchers and hospital sites across canada have just gotten approval to start collecting blood plasma for covid-19. they hope to see their first donors within a week. the initiative was the result of universities, researchers, and doctors across the country working around the clock to organize a trial. it took less than a month — an incredible feat that would normally take at least a year and a half, says dr. jeannie callum , a transfusion medicine specialist at sunnybrook health sciences centre and professor at the university of toronto.
advertisement
people who have recovered from covid-19 can fill out an online registry at https://blood.ca/en/convalescentplasma or email blood4research@blood.ca with their contact information so canadian blood services can respond with details. researchers only want to hear from those who have been confirmed positive.
advertisement
the most common issues with plasma donation is fluid overload , which can cause increased blood pressure and respiratory distress. however, there is less risk with covid-19 plasma donations because the amount given to patients is less than usual. typically, one litre is given to adult patients during blood transfusions, but only half a litre will be given to covid-19 patients in this trial.
advertisement
so far, a small study from china has reported improvement in severely ill patients and no adverse effects. another small study on five patients found promising results . researchers from the u.s. are running controlled trials to see whether patients who receive plasma recover faster than patients who don’t. south korea, france, and the u.k. are also currently running trials.
advertisement